Cable Hill Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Cable Hill Partners’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-250	Closed	-$3K	–	796
2018 Q2	$3K	Sell	250 -750	-75%	-$8.37K	﹤0.01%	765
2018 Q1	$10K	Buy	+1,000	New	+$9.46K	﹤0.01%	483
2017 Q4	–	Sell	-800	Closed	-$13K	–	944
2017 Q3	$13K	Hold	800	–	–	0.01%	510
2017 Q2	$10K	Hold	800	–	–	0.01%	404
2017 Q1	$17K	Hold	800	–	–	0.01%	280
2016 Q4	$11K	Hold	800	–	–	0.01%	381
2016 Q3	$13K	Buy	800 +400	+100%	+$5.77K	0.01%	361
2016 Q2	$6K	Buy	+400	New	+$5.4K	﹤0.01%	464

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Cable Hill Partners's CRVS Position: Q3 2018 in Review

Cable Hill Partners sold out of Corvus Pharmaceuticals (CRVS) in Q3 2018, closing a stake of 250 shares — an estimated $3K sold.

Cable Hill Partners first reported a position in CRVS in Q2 2016 and held it in 8 quarters. The position peaked at $17K in Q1 2017. 61 funds tracked by Wall St. Rank hold CRVS as of Q3 2018.

Cable Hill Partners reported no remaining Corvus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Cable Hill Partners sold 250 Corvus Pharmaceuticals shares in Q3 2018, an estimated $3K.
Cable Hill Partners first reported a position in Corvus Pharmaceuticals in Q2 2016 and held it in 8 quarters.
Cable Hill Partners's Corvus Pharmaceuticals position peaked at $17K in Q1 2017.
61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.